ERBB2 and gastric cancer: Furthermore, the objective response rate was considerably enhanced in HER2‐positive unresectable advanced GC through the incorporation of pembrolizumab alongside trastuzumab and chemotherapy, as evidenced by the KEYNOTE‐811 clinical trial.30